CeriBell (NASDAQ:CBLL) VP David Foehr Sells 5,556 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 5,556 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $20.00, for a total value of $111,120.00. Following the completion of the sale, the vice president owned 18,900 shares in the company, valued at $378,000. This trade represents a 22.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

David Foehr also recently made the following trade(s):

• On Monday, January 5th, David Foehr sold 5,556 shares of CeriBell stock. The stock was sold at an average price of $22.60, for a total transaction of $125,565.60.
• On Wednesday, December 3rd, David Foehr sold 5,265 shares of CeriBell stock. The stock was sold at an average price of $16.83, for a total transaction of $88,609.95.

CeriBell Stock Down 2.0%

Shares of NASDAQ CBLL traded down $0.39 during midday trading on Friday, hitting $18.95. 6,490 shares of the stock traded hands, compared to its average volume of 358,838. CeriBell, Inc. has a one year low of $10.01 and a one year high of $26.04. The business has a 50 day moving average price of $21.10 and a two-hundred day moving average price of $15.65. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.25 and a current ratio of 12.65. The company has a market cap of $702.90 million, a PE ratio of -12.58 and a beta of 1.03.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. The firm had revenue of $22.59 million for the quarter, compared to analyst estimates of $21.78 million. On average, equities analysts predict that CeriBell, Inc. will post -2.46 EPS for the current year.

Institutional Trading of CeriBell

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of CeriBell by 11.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after acquiring an additional 147,013 shares in the last quarter. Yu Fan boosted its position in shares of CeriBell by 10.7% in the 2nd quarter. Yu Fan now owns 1,353,166 shares of the company’s stock worth $25,345,000 after purchasing an additional 130,964 shares in the last quarter. Novo Holdings A S grew its stake in shares of CeriBell by 2.3% in the 2nd quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock worth $16,857,000 after buying an additional 20,000 shares during the last quarter. TimesSquare Capital Management LLC grew its holdings in shares of CeriBell by 2.6% during the third quarter. TimesSquare Capital Management LLC now owns 817,645 shares of the company’s stock valued at $9,395,000 after buying an additional 20,700 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in CeriBell by 41.8% in the 3rd quarter. Millennium Management LLC now owns 666,448 shares of the company’s stock worth $7,657,000 after acquiring an additional 196,299 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Canaccord Genuity Group upped their price target on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. BTIG Research restated a “buy” rating and set a $30.00 price target on shares of CeriBell in a research report on Wednesday, January 28th. Raymond James Financial began coverage on CeriBell in a report on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 price objective on the stock. TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Finally, JPMorgan Chase & Co. dropped their price objective on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $24.67.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.